RU96117381A - NEUROPROTECTIVE COMPOUNDS - Google Patents

NEUROPROTECTIVE COMPOUNDS

Info

Publication number
RU96117381A
RU96117381A RU96117381/04A RU96117381A RU96117381A RU 96117381 A RU96117381 A RU 96117381A RU 96117381/04 A RU96117381/04 A RU 96117381/04A RU 96117381 A RU96117381 A RU 96117381A RU 96117381 A RU96117381 A RU 96117381A
Authority
RU
Russia
Prior art keywords
disease
compound according
condition
hydroxypiperidin
chroman
Prior art date
Application number
RU96117381/04A
Other languages
Russian (ru)
Other versions
RU2126404C1 (en
Inventor
В.Батлер Тодд
Л. Ченард Бертранд
Original Assignee
Пфайзер Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк filed Critical Пфайзер Инк
Priority claimed from PCT/IB1994/000365 external-priority patent/WO1995020587A1/en
Publication of RU96117381A publication Critical patent/RU96117381A/en
Application granted granted Critical
Publication of RU2126404C1 publication Critical patent/RU2126404C1/en

Links

Claims (17)

1. 3R*4S*3-[4-(4-фторфенил)-4-гидроксипиперидин-1-ил]-хроман-4, 7-диол, его оптические изомеры и фармацевтически приемлемые соли.1. 3R * 4S * 3- [4- (4-fluorophenyl) -4-hydroxypiperidin-1-yl] -chroman-4, 7-diol, its optical isomers and pharmaceutically acceptable salts. 2. Соединение по п. 1, которое представляет собой рацемический 3R*4S*3-[4-(4-фторфенил)-4-гидроксипиперидин-1-ил]хроман-4, 7-диол.2. The compound according to claim 1, which is a racemic 3R * 4S * 3- [4- (4-fluorophenyl) -4-hydroxypiperidin-1-yl] chroman-4, 7-diol. 3. Соединение по п. 1, которое представляет собой (+) 3R 4S 3-[4-(4-фторфенил)-4-гидроксипиперидин-1-ил]-хроман-4,7-диол. 3. The compound according to claim 1, which is (+) 3R 4S 3- [4- (4-fluorophenyl) -4-hydroxypiperidin-1-yl] -chroman-4,7-diol. 4. Соединение по п. 1, которое представляет собой (-) 4R3S 3-[4-(4-фторфенил)-4-гидроксипиперидин-1-ил]-хроман-4,7-диол. 4. The compound of claim 1, which is (-) 4R3S 3- [4- (4-fluorophenyl) -4-hydroxypiperidin-1-yl] -chroman-4,7-diol. 5. Фармацевтическая композиция, содержащая нейропротекторное количество соединения по п.1 и фармацевтически приемлемый носитель. 5. A pharmaceutical composition comprising a neuroprotective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier. 6. Фармацевтическая композиция, содержащая нейропротекторное количество соединения по п.2 и фармацевтически приемлемый носитель. 6. A pharmaceutical composition comprising a neuroprotective amount of a compound according to claim 2 and a pharmaceutically acceptable carrier. 7. Фармацевтическая композиция, содержащая нейропротекторное количество соединения по п.3 и фармацевтически приемлемый носитель. 7. A pharmaceutical composition comprising a neuroprotective amount of a compound according to claim 3 and a pharmaceutically acceptable carrier. 8. Фармацевтическая композиция по п.5, отличающаяся тем, что она предназначена для перорального приема. 8. The pharmaceutical composition according to claim 5, characterized in that it is intended for oral administration. 9. Способ блокирования участков рецепторов NMDA у млекопитающих, нуждающихся в таком блокировании, включающий в себя введение указанному млекопитающему эффективного количества соединения по п.1. 9. A method of blocking portions of NMDA receptors in mammals in need of such blocking, comprising administering to said mammal an effective amount of a compound according to claim 1. 10. Способ лечения заболевания или состояния у млекопитающего, которое чувствительно к лечению путем блокирования участков рецепторов NMDA, включающий в себя введение указанному млекопитающему эффективного количества соединения по п.1. 10. A method of treating a disease or condition in a mammal that is sensitive to treatment by blocking portions of NMDA receptors, comprising administering to said mammal an effective amount of a compound according to claim 1. 11. Способ по п.10, отличающийся тем, что указанное заболевание или состояние выбирают из группы, состоящей из травмы головы, травмы спинного мозга, инсульта и мультиинфарктной деменции. 11. The method of claim 10, wherein said disease or condition is selected from the group consisting of head injury, spinal cord injury, stroke and multi-infarction dementia. 12. Способ по п.10, отличающийся тем, что указанное заболевание или состояние выбирают из группы, состоящей из болезни Альцгеймера, болезни Хантингтона, болезни Паркинсона, эпилепсии и амиотропного латерального склероза. 12. The method of claim 10, wherein said disease or condition is selected from the group consisting of Alzheimer's disease, Huntington's disease, Parkinson's disease, epilepsy and amyotropic lateral sclerosis. 13. Способ по п.10, отличающийся тем, что указанное заболевание или состояние выбирают из группы, состоящей из боли, деменции, связанной со СПИДом, психотических состояний, привыкания к чрезмерному употреблению лекарственных средств, мигрени, гипогликемии и тревожных состояний. 13. The method of claim 10, wherein said disease or condition is selected from the group consisting of pain, AIDS-related dementia, psychotic conditions, addiction to excessive drug use, migraine, hypoglycemia, and anxiety conditions. 14. Способ по п.10, отличающийся тем, что указанное заболевание или состояние является недержанием мочи. 14. The method of claim 10, wherein said disease or condition is urinary incontinence. 15. Способ по п.10, отличающийся тем, что указанное заболевание или состояние является ишемическим эпизодом, вызванным оперативным вмешательством на ЦНС, оперативным вмешательством на открытом сердце или любой процедурой, во время которой затрагивается функция сердечно-сосудистой системы. 15. The method according to claim 10, characterized in that said disease or condition is an ischemic episode caused by surgery on the central nervous system, surgery on an open heart or any procedure during which the function of the cardiovascular system is affected. 16. Способ по п.13, отличающийся тем, что указанное заболевание или состояние является мигренью. 16. The method according to item 13, wherein the specified disease or condition is a migraine. 17. Соединение по п.1, которое представляет собой (+) (3R, 4S)-3-[4-(4-фторфенил)-4-гидроксипиперидин-1-ил] хроман-4,7-диол тартрат этанолат гидрат. 17. The compound according to claim 1, which is (+) (3R, 4S) -3- [4- (4-fluorophenyl) -4-hydroxypiperidin-1-yl] chroman-4,7-diol tartrate ethanolate hydrate.
RU96117381A 1994-01-31 1994-11-21 3r*,4s* 3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1- yl)chrohan-4,7-diol, optical isomers thereof and pharmaceutical composition based thereon, and method of medical treatment RU2126404C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31
US08/189,479 1994-01-31
PCT/IB1994/000365 WO1995020587A1 (en) 1994-01-31 1994-11-21 Neuroprotective chroman compounds

Publications (2)

Publication Number Publication Date
RU96117381A true RU96117381A (en) 1998-12-10
RU2126404C1 RU2126404C1 (en) 1999-02-20

Family

ID=22697514

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96117381A RU2126404C1 (en) 1994-01-31 1994-11-21 3r*,4s* 3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1- yl)chrohan-4,7-diol, optical isomers thereof and pharmaceutical composition based thereon, and method of medical treatment

Country Status (27)

Country Link
US (1) US5744483A (en)
EP (1) EP0741724B1 (en)
JP (1) JP2866743B2 (en)
CN (1) CN1048247C (en)
AT (1) ATE183184T1 (en)
AU (1) AU684568B2 (en)
BR (2) BR9408506A (en)
CA (1) CA2182101C (en)
CO (1) CO4230161A1 (en)
CZ (1) CZ286757B6 (en)
DE (1) DE69420053T2 (en)
DK (1) DK0741724T3 (en)
EG (1) EG20672A (en)
ES (1) ES2134361T3 (en)
FI (1) FI113769B (en)
GR (1) GR3031356T3 (en)
HU (1) HU221633B1 (en)
IL (1) IL112415A (en)
MY (1) MY111623A (en)
NO (1) NO309190B1 (en)
NZ (1) NZ275151A (en)
PE (1) PE43795A1 (en)
PL (1) PL179448B1 (en)
RU (1) RU2126404C1 (en)
TW (1) TW449591B (en)
WO (1) WO1995020587A1 (en)
ZA (1) ZA95692B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232059A1 (en) * 1995-09-15 1997-03-20 Bertrand Leo Chenard Phenol derivatives with pharmaceutical activity
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
SE0100902D0 (en) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
ATE473967T1 (en) * 2003-11-26 2010-07-15 Pfizer Prod Inc AMINOPYRAZOLE DERIVATIVES AS GSK-3 INHIBITORS
WO2007051735A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
CN102702044A (en) * 2006-01-20 2012-10-03 先灵公司 Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
EP2522647B1 (en) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Process of separating chiral isomers of chroman compounds and their derivatives and precursors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (en) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (en) * 1978-07-03 1980-02-07 Sandoz Ag 3-aminopropoxy-aryl derivates,preparation and use thereof
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (en) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim NEW 8-ARYLALKYL-3-PHENYL-3-NORTROPANOLE, THE ACID ADDITION SALTS THEREOF, THE MEDICINAL PRODUCTS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION THEREOF
EP0076075B1 (en) * 1981-09-25 1986-11-20 Beecham Group Plc Pharmaceutically active benzopyran compounds
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2581993B1 (en) * 1985-05-14 1988-03-18 Synthelabo (BENZOYL-4 PIPERIDINO) -2 PHENYL-1 ALCANOLS DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (en) * 1988-07-12 1992-07-10 Synthelabo INDOLONES-2, QUINOLEINONES-2, BENZO (B) AZEPINONES-2 AND BENZIMIDAZOLONES-2 DERIVATIVES OF (HYDROXY-1 PIPERIDINYL-2 ALKYL), THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
SK232890A3 (en) * 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
RU2099339C1 (en) * 1990-02-06 1997-12-20 Пфайзер Инк. Piperidine derivative
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Similar Documents

Publication Publication Date Title
RU2003128535A (en) HETEROPOLYCYCLIC COMPOUND (OPTIONS), PHARMACEUTICAL COMPOSITION (OPTIONS) AND METHOD FOR TREATING A DISEASE ASSOCIATED WITH ACTIVATION OF METABOTROPIC GLUTAMATE RECEPTORS (VARIANS)
JP2009526821A (en) Novel pharmaceutical composition for the treatment of attention deficit hyperactivity disorder
EA200300514A1 (en) PHARMACEUTICAL COMPOSITIONS OF NMDA RECEPTORS AGONIST
JP5837726B1 (en) Rehabilitation effect promoter after nerve injury containing alkyl ether derivative or salt thereof
RU98102116A (en) (1S, 2S) -1- (4-HYDROXYPHENYL) -2- (4-HYDROXY-4-Phenylpiperidin-1-IL) -1-PROPANO LMETANSULPHONATE TRIHYDRATE
RU94044671A (en) Use of nonpeptide antagonists of tachykinin receptors
RU97102362A (en) NEUROPROTECTIVE DERIVATIVES 3- (PIPERIDINYL-1) -CHROMAN-4,7-DIOL AND 1- (4-HYDROXYPHENYL) -2- (PIPERIDINYL-1) -ALCANOL
RU96117381A (en) NEUROPROTECTIVE COMPOUNDS
NO333610B1 (en) Use of alpha-aminamide derivatives in the manufacture of a medicament for the treatment of headache conditions
DE69434889D1 (en) Compounds acting on a new site of receptor-dependent calcium channels for the treatment of neurological disorders
RU2008101923A (en) TRICYCLIC BENZIMIDAZOLE AND THEIR APPLICATION AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR
JP2003528095A5 (en)
JP4351909B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a medicament
RU2006138495A (en) USE OF RECEPTOR AGONISTS ACTIVATED BY DELTA PEROXISOMIS PROLIFERATOR FOR TREATMENT OF PC AND OTHER DEMIELINIZING DISEASES
KR970705542A (en) Neuroprotective 3- (piperidinyl-1) -chroman-4,7-diol and 1- (4-hydrophenyl) -2- (piperidinyl-1) -alkanol derivative (NEUROPROTECTIVE 3- -1) -CHROMAN-4,7-DIOL AND 1- (4-HYDROPHENYL) -2- (PIPERIDINYL-1) -ALCANOL DERIVATIVES
RU96121937A (en) DERIVATIVES OF TROPAN-2-ALDOXIM AS REQUIRED INHIBITORS OF REVERSE CAPTURE OF NEUROTREMITTERS
RU2001126570A (en) Derivatives of 1-arensulfonyl-2-arylpyrrolidine and piperidine for the treatment of disorders of the central nervous system
RU96111003A (en) DERIVATIVES N-ACYL-2-ARYLCYCLOPROPYLMETYLAMINE, STIMULATING MELATONIN SYNTHESIS, PHARMACEUTICAL COMPOSITION, RADIOLIGAND AND METHOD OF TREATMENT
JPH10512252A (en) Enantiomer of 1- (3,4-dichlorobenzyl) -2-methylaminoindan
YU6196A (en) Transdermal band-aid formulation
JP2008517907A5 (en)
AU779152B2 (en) Prophylactic use of N-methyl-D-aspartate (NMDA) antagonists
IE67814B1 (en) Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases
JP3043807B2 (en) Compounds for the treatment of age-related memory disorders and other cognitive disorders
ATE260656T1 (en) NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEURONAL DAMAGE AND STROKE